<DOC>
	<DOCNO>NCT00518323</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability 3 weight-based , fixed-dose group paliperidone extend release ( ER ) compare placebo adolescent patient 12 17 year age , diagnose schizophrenia . Paliperidone ER atypical antipsychotic agent approve U.S. Food Drug Administration treatment schizophrenia adult . Patients may voluntary inpatient outpatient time screen visit , return usual living situation Day 21 double-blind treatment phase . The study duration approximately 10 week . Patients complete study discontinue study due lack efficacy complete least 21 day double-blind treatment expect benefit paliperidone treatment , may enter optional open-label safety study .</brief_summary>
	<brief_title>A Double-blind , Placebo-controlled Study Safety Efficacy Paliperidone Extended Release ( ER ) Treatment Schizophrenia Adolescent Patients</brief_title>
	<detailed_description>The study multicenter , randomize ( treatment group assign chance ) , double-blind ( neither physician patient know treatment group patient ) , parallel-group , placebo control study . This study enroll adolescent men woman schizophrenia specify Diagnostic Statistical Manual Mental Disorders ; 4th Edition ( DSM-IV ) diagnosis schizophrenia ( 295.10 , 295.20 , 295.30 , 295.60 , 295.90 ) confirm Kiddie-Sads-Present Lifetime Version ( KSADS-PL ) , Positive Negative Syndrome Scale ( PANSS ) score 60 120 , inclusive , screen baseline . Before study related procedure perform , patient parent legal guardian must provide assent sign informed consent form , respectively . The study consist 3 phase : screening phase , 6-week double-blind treatment phase end-of-study early withdrawal visit , 1 week follow-up visit patient enter optional open-label safety study . In screen phase , trained clinician complete K SADS-PL interview , include 5 supplement , confirm DSM-IV diagnostic criterion schizophrenia . In addition , K-SADS-PL screen diagnostic interview item suicide must score &lt; =2 , follow : item ) , recurrent thought death ; item b ) , suicidal thought ; item c ) , suicide attempt seriousness ; item ) , suicide attempt lethality ; item e ) self harm behavior . Women childbearing potential undergo urine pregnancy test screening , baseline , Week 4 , end study upon early withdrawal study . Patients receive prohibited medication , antidepressant , lithium , drug abuse , alcohol , enter washout period medication taper eventually stop . The screen washout phase may exceed 21 day . In double-blind treatment phase , baseline visit , inclusion exclusion criterion review . Patients continue meet criterion randomly assign ( toss coin ) 1 4 dose group . Patients weigh 29 &lt; 51 kilogram ( kg ) receive paliperidone ER 1.5 , 3.0 , 6.0 milligram ( mg ) match placebo . Patients weigh &gt; =51 kg receive paliperidone ER 1.5 , 6.0 , 12.0 mg match placebo . Patients come study site weekly visit phase . A follow-up visit occur 1 week end treatment patient enter open-label study . Efficacy safety procedure perform specify time study . Efficacy procedures include administration PANSS , Children 's Global Assessment ( CGAS ) , Clinical Global Impression-Severity ( CGI-S ) sleep visual analog scale . Safety assessment include physical examination ( ECG measurement , vital sign , weight , height , waist measurement ) , clinical laboratory testing , drug screen , Simpson Angus Scale ( SAS ) , Barnes Akathisia Rating Scale ( BARS ) , Abnormal Involuntary Movement Scale ( AIMS ) , Tanner Staging , concomitant medication record adverse event . A Data Safety Monitoring Board oversee conduct study review adverse event report laboratory test result . The total volume blood drawn laboratory evaluation throughout study , include 10 milliliter ( mL ) optional pharmacogenomics test , approximately 66 mL patient . Blood sample collect explore pharmacokinetics paliperidone adolescent patient . The study hypothesis least 1 paliperidone ER dose group superior placebo improve symptom schizophrenia measure change total PANSS score baseline endpoint ( Week 6 ) . Paliperidone ER 1.5 , 3.0 , 6.0 , 12.0 mg match placebo administer daily morning 10 a.m. , approximately time day . Study drug administration occur consistent manner relative intake food ( i.e. , either breakfast , without breakfast ) throughout study . Study drug swallow whole water . Study drug administer 6 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Must meet Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSM IV ) criterion schizophrenia ( 295.10 , 295.20 , 295.30 , 295.60 , 295.90 ) 1 year ( diagnosis establish use KSADSPL , include supplement ) Must danger others , must family support available maintain outpatient Should least 1 adequate treatment antipsychotic participation study Must PANSS score 60 120 , inclusive , screen baseline Weight &gt; =29 kg Meet DSMIV criterion screen dissociative disorder , bipolar disorder , major depressive disorder , schizoaffective disorder , schizophreniform disorder , autistic disorder , primary substance induce psychotic disorder . Other comorbid disorder e.g. , attentiondeficit hyperactivity disorder ( ADHD ) allow long diagnosis schizophrenia primary diagnosis comorbid disorder investigator 's judgment require medication Mild , moderate , severe mental retardation ( i.e. , document intelligence quotient [ IQ ] &lt; 70 ) establish previous IQ test history Women pregnant ( confirm urine pregnancy test perform screen baseline ) , plan become pregnant nursing Have know suspected history seizure disorder , neuroleptic malignant syndrome , encephalopathic syndrome , tardive dyskinesia , insulin dependent diabetes mellitus Presence significant unstable cardiovascular , respiratory , renal , hepatic , hematologic , endocrine , immunologic , systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic</keyword>
</DOC>